Processa Pharmaceuticals (NASDAQ: PCSA) reported an insider purchase by Chief Administrative Officer Wendy Guy, who acquired 1,583 shares of common stock in a single transaction dated April 15, 2026. The shares were purchased at $2.97 apiece, bringing the total outlay for the trade to $4,701.
Following this transaction, Guy's direct ownership in Processa stands at 4,693 shares. In addition to her direct holdings, she is recorded as having an indirect interest in 333 shares via CorLyst, LLC.
On a market basis, PCSA is trading at $3.10 at the time of the report. That price represents an 11.91% gain over the past week, yet the stock remains 59% lower compared with its level six months ago, reflecting notable depreciation over that intermediate timeframe.
An InvestingPro analysis included with the report characterizes Processa Pharmaceuticals as appearing undervalued at current price levels. The same analysis highlights the company's balance sheet posture, indicating that the company holds more cash than debt. Investors using InvestingPro can access an additional nine tips and a range of financial metrics specific to PCSA.
The disclosed purchase and the accompanying ownership details provide a snapshot of insider activity at the company, while the price movements over recent periods and the InvestingPro valuation view give context for market and balance sheet dynamics.
Contextual note - The figures and positions above are taken from the filing and the accompanying analysis. The transaction date, share count, per-share price, resulting ownership totals, recent market performance, and the InvestingPro valuation comment are the factual elements reported.